Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 10/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | RARA | P10276 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | GCGR | P47871 | 1/20 | 0.54 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.54 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190256 | 1.00 | RARB (0.68) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL27585162 | 0.95 | RARB (0.60) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL10979945 | 0.85 | GCGR (0.48) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL20704868 | 0.81 | RARB (0.46) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL4330679 | 0.81 | RARB (1.00) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL7575190 | 0.81 | HCAR3 (0.62) | MAPTHCAR3PLA2G4B | |
| SCHEMBL9779790 | 0.81 | HCAR3 (0.62) | MAPTHCAR3PLA2G4B | |
| SCHEMBL18612200 | 0.81 | GCGR (0.44) | RARBALDH1A1MAPTGCGRPLK1 | |
| SCHEMBL9557826 | 0.80 | CASP6 (0.66) | MAPTHCAR3 | |
| SCHEMBL13779190 | 0.80 | RARB (1.00) | RARBMEN1ALDH1A1RARAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | SONY CORPORATION (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1907347-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | Arcadia Pharmaceuticals Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009083-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | RARB, RARA, RARG | RARB 1/4885MEN1 4845/4885ALDH1A1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.